CD47 and ovarian cancer: First, co‐administering inhibitors targeting myeloid‐specific immune checkpoints, such as antibodies against CD47, SIGLEC family and LILRB family, can further enhance the cytotoxic capacity of CAR‐macrophages.[60] For example, combining iPSC‐derived CAR‐macrophages with anti‐CD47 antibodies has been shown to induce significant tumor regression in ovarian cancer models.[61] Second, using immune checkpoint inhibitors targeting the PD‐1/PD‐L1 and CTLA‐4 pathways can block tumor‐mediated immune evasion and enhance T cell‐mediated anti‐tumor immunity.